Denali Therapeutics (DNLI) Cash from Investing Activities (2017 - 2026)

Denali Therapeutics (DNLI) has reported Cash from Investing Activities for 10 consecutive years, with $94.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 403.84% year-over-year to $94.5 million; the TTM figure through Mar 2026 stood at $331.0 million (down 13.62% YoY), while the FY2025 annual figure was $255.3 million, up 387.62% from the prior year.
• Cash from Investing Activities climbed to $94.5 million in Q1 2026 per DNLI's latest filing, from $20.8 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $172.2 million in Q4 2024 and bottomed at -$453.2 million in Q1 2024.
• Historically, Cash from Investing Activities has averaged $21.7 million across 5 years, with a median of $73.0 million in 2023.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 554.45% — and 2024, when it sank 388.8%.
• Denali Therapeutics' Cash from Investing Activities stood at -$127.6 million in 2022, then surged by 157.27% to $73.0 million in 2023, then soared by 135.75% to $172.2 million in 2024, then tumbled by 87.94% to $20.8 million in 2025, then jumped by 354.83% to $94.5 million in 2026.
• Business Quant data shows DNLI's Cash from Investing Activities at $94.5 million in Q1 2026, $20.8 million in Q4 2025, and $57.8 million in Q3 2025.